tetano
Editor, Senior Moderator
Arch Virol
. 2023 Jun 23;168(7):190.
doi: 10.1007/s00705-023-05812-8. Broad humoral immunity generated in mice by a formulation composed of two antigens from the Delta variant of SARS-CoV-2
Yadira Lobaina[SUP] 1 2 [/SUP], Rong Chen[SUP] 1 3 [/SUP], Edith Suzarte[SUP] 4 [/SUP], Panchao Ai[SUP] 1 3 [/SUP], Vivian Huerta[SUP] 1 4 [/SUP], Changyuan Tan[SUP] 1 3 [/SUP], Liz Alvarez-Lajonchere[SUP] 4 [/SUP], Yang Liling[SUP] 5 [/SUP], Alexis Musacchio[SUP] 1 4 [/SUP], Ricardo Silva[SUP] 1 6 [/SUP], Gerardo Guillén[SUP] 4 [/SUP], Jiang Zaixue[SUP] 7 [/SUP], Ke Yang[SUP] 8 9 [/SUP], Yasser Perera[SUP] 10 11 12 [/SUP], Lisset Hermida[SUP] 13 14 15 [/SUP]
Affiliations
Due to the rapid development of new variants of SARS-CoV-2 as well as the real threat of new coronavirus zoonosis events, the development of a preventive vaccine with a broader scope of functionality is highly desirable. Previously, we reported the functionality of a nasal formulation containing the nucleocapsid protein and the receptor-binding domain (RBD) of the spike protein of the Delta variant of SARS-CoV-2 combined with the ODN-39M adjuvant. This combination induced cross-reactive immunity in mucosal and systemic compartments at the sarbecovirus level. In the present study, we explored the magnitude of the immunity generated in BALB/c mice by the same formulation with alum added as an additional adjuvant, to enhance the humoral immunity against the two antigens. Animals were immunized with three doses of the bivalent formulation, administered by subcutaneous route. Humoral immunity was tested by ELISA, and the neutralizing capacity of the resulting antibodies (Abs) was evaluated using a surrogate test and a vesicular stomatitis virus (VSV) pseudovirus-based assay. Cell-mediated immunity was also investigated using an IFN-γ ELISpot assay. High levels of antibodies against both antigens (N and RBD) were obtained upon immunization. Anti-RBD Abs with neutralizing capacity reacted with the RBD of three SARS-CoV-2 variants tested, including Omicron. Abs recognizing the nucleocapsid proteins of SARS-CoV-1 and the SARS-CoV-2 Delta and Omicron variants were also detected. Taken together, these results suggest that this bivalent formulation could be an attractive component of a pancorona vaccine able to broaden the scope of humoral immunity against both antigens. This will be particularly important for the reinforcement of immunity in previously vaccinated and/or infected populations.
. 2023 Jun 23;168(7):190.
doi: 10.1007/s00705-023-05812-8. Broad humoral immunity generated in mice by a formulation composed of two antigens from the Delta variant of SARS-CoV-2
Yadira Lobaina[SUP] 1 2 [/SUP], Rong Chen[SUP] 1 3 [/SUP], Edith Suzarte[SUP] 4 [/SUP], Panchao Ai[SUP] 1 3 [/SUP], Vivian Huerta[SUP] 1 4 [/SUP], Changyuan Tan[SUP] 1 3 [/SUP], Liz Alvarez-Lajonchere[SUP] 4 [/SUP], Yang Liling[SUP] 5 [/SUP], Alexis Musacchio[SUP] 1 4 [/SUP], Ricardo Silva[SUP] 1 6 [/SUP], Gerardo Guillén[SUP] 4 [/SUP], Jiang Zaixue[SUP] 7 [/SUP], Ke Yang[SUP] 8 9 [/SUP], Yasser Perera[SUP] 10 11 12 [/SUP], Lisset Hermida[SUP] 13 14 15 [/SUP]
Affiliations
- PMID: 37351679
- DOI: 10.1007/s00705-023-05812-8
Due to the rapid development of new variants of SARS-CoV-2 as well as the real threat of new coronavirus zoonosis events, the development of a preventive vaccine with a broader scope of functionality is highly desirable. Previously, we reported the functionality of a nasal formulation containing the nucleocapsid protein and the receptor-binding domain (RBD) of the spike protein of the Delta variant of SARS-CoV-2 combined with the ODN-39M adjuvant. This combination induced cross-reactive immunity in mucosal and systemic compartments at the sarbecovirus level. In the present study, we explored the magnitude of the immunity generated in BALB/c mice by the same formulation with alum added as an additional adjuvant, to enhance the humoral immunity against the two antigens. Animals were immunized with three doses of the bivalent formulation, administered by subcutaneous route. Humoral immunity was tested by ELISA, and the neutralizing capacity of the resulting antibodies (Abs) was evaluated using a surrogate test and a vesicular stomatitis virus (VSV) pseudovirus-based assay. Cell-mediated immunity was also investigated using an IFN-γ ELISpot assay. High levels of antibodies against both antigens (N and RBD) were obtained upon immunization. Anti-RBD Abs with neutralizing capacity reacted with the RBD of three SARS-CoV-2 variants tested, including Omicron. Abs recognizing the nucleocapsid proteins of SARS-CoV-1 and the SARS-CoV-2 Delta and Omicron variants were also detected. Taken together, these results suggest that this bivalent formulation could be an attractive component of a pancorona vaccine able to broaden the scope of humoral immunity against both antigens. This will be particularly important for the reinforcement of immunity in previously vaccinated and/or infected populations.